company background image
ALNY

Alnylam PharmaceuticalsNasdaqGS:ALNY Stock Report

Last Price

US$136.41

Market Cap

US$16.3b

7D

-8.1%

1Y

-20.9%

Updated

21 Jan, 2022

Data

Company Financials +
ALNY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ALNY Stock Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics.

Alnylam Pharmaceuticals Competitors

Amgen

NasdaqGS:AMGN

US$128.3b

Moderna

NasdaqGS:MRNA

US$64.9b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$15.5b

Sarepta Therapeutics

NasdaqGS:SRPT

US$5.5b

Price History & Performance

Summary of all time highs, changes and price drops for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$136.41
52 Week HighUS$212.00
52 Week LowUS$125.08
Beta0.87
1 Month Change-27.20%
3 Month Change-31.32%
1 Year Change-20.87%
3 Year Change64.25%
5 Year Change258.13%
Change since IPO2,169.72%

Recent News & Updates

Shareholder Returns

ALNYUS BiotechsUS Market
7D-8.1%-7.4%-6.1%
1Y-20.9%-22.0%4.2%

Return vs Industry: ALNY matched the US Biotechs industry which returned -20% over the past year.

Return vs Market: ALNY underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is ALNY's price volatile compared to industry and market?
ALNY volatility
ALNY Average Weekly Movement9.4%
Biotechs Industry Average Movement10.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ALNY's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021,453Yvonne Greenstreethttps://www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).

Alnylam Pharmaceuticals Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
ALNY fundamental statistics
Market CapUS$16.31b
Earnings (TTM)-US$837.90m
Revenue (TTM)US$749.31m

21.8x

P/S Ratio

-19.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALNY income statement (TTM)
RevenueUS$749.31m
Cost of RevenueUS$125.50m
Gross ProfitUS$623.81m
ExpensesUS$1.46b
Earnings-US$837.90m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-7.01
Gross Margin83.25%
Net Profit Margin-111.82%
Debt/Equity Ratio57.4%

How did ALNY perform over the long term?

See historical performance and comparison

Valuation

Is Alnylam Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALNY ($136.41) is trading below our estimate of fair value ($479.11)

Significantly Below Fair Value: ALNY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALNY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALNY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALNY is overvalued based on its PB Ratio (21.6x) compared to the US Biotechs industry average (2x).


Future Growth

How is Alnylam Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

61.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALNY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ALNY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALNY's is expected to become profitable in the next 3 years.

Revenue vs Market: ALNY's revenue (33.5% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: ALNY's revenue (33.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALNY is forecast to be unprofitable in 3 years.


Past Performance

How has Alnylam Pharmaceuticals performed over the past 5 years?

-16.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALNY is currently unprofitable.

Growing Profit Margin: ALNY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.

Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ALNY has a negative Return on Equity (-110.85%), as it is currently unprofitable.


Financial Health

How is Alnylam Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ALNY's short term assets ($2.7B) exceed its short term liabilities ($610.7M).

Long Term Liabilities: ALNY's short term assets ($2.7B) exceed its long term liabilities ($2.1B).


Debt to Equity History and Analysis

Debt Level: ALNY has more cash than its total debt.

Reducing Debt: ALNY's debt to equity ratio has increased from 14.8% to 57.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALNY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALNY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Alnylam Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALNY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALNY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALNY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Yvonne Greenstreet (58 yo)

no data

Tenure

US$3,034,001

Compensation

Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. She has been a Director of Alnylam Pharmaceuticals, Inc. since October 28, 2021. S...


CEO Compensation Analysis

Compensation vs Market: Yvonne's total compensation ($USD3.03M) is below average for companies of similar size in the US market ($USD11.42M).

Compensation vs Earnings: Yvonne's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALNY's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ALNY's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Alnylam Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Alnylam Pharmaceuticals, Inc.
  • Ticker: ALNY
  • Exchange: NasdaqGS
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$16.315b
  • Shares outstanding: 119.60m
  • Website: https://www.alnylam.com

Number of Employees


Location

  • Alnylam Pharmaceuticals, Inc.
  • 675 West Kendall Street
  • Henri A. Termeer Square
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:43
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.